- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02121470
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
Acute Kidney Injury (AKI) is a common and severe complication in critically ill patients which is associated with increased morbidity and mortality as well as high costs of medical care.
NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is a biomarker, that is expressed in several tissues including the kidneys. Renal expression of NGAL is dramatically increased in kidney injury from a variety of causes, and NGAL is released into both urine and plasma. NGAL levels rise within two hours of the insult, making NGAL an early and sensitive biomarker of kidney injury, with the potential to assist clinicians in managing patients at risk of kidney injury.
This study is designed to validate the assigned NGAL cutoff value by comparing to clinical diagnosis of AKI as determined by current clinical practice in the US.
The study sites will enroll consecutive ICU patients. Patients are given standard clinical care and lab-work. Each day, one additional urine and two additional plasma samples will be drawn and frozen. These additional samples are shipped to Sponsor for retrospective NGAL measurements.
The duration of each subject´s participation will be until discharge from the ICU, or for a maximum 8 days, whichever comes first. In addition serum creatinine values will continue to be collected manually from the hospital data system for 48 hours after discharge from the ICU. (If subject has been in ICU for 8 or more days, the follow up values are collected while the patient is still in the ICU).
250 subjects will be enrolled in total at the three investigator sites. At least 40 patients must be enrolled at each site.
The NGAL value will be matched to the "clinical diagnosis" of acute kidney injury (AKI) as specified by KDIGO® guidelines. The clinical diagnosis will be assigned by a three-person adjudication panel based on the entries in the eCRF by the investigators. Adjudicators are blinded for investigation site, AKI-diagnosis by treating physician, and NGAL values.
A comparison of AKI diagnosis based on the cutoff value 250 ng/mL and clinical diagnosis as assigned by the majority of the adjudication panel will be conducted.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
AKI is a common and severe complication in critically ill patients, which is associated with increased morbidity and mortality as well as high costs of medical care.
Despite efforts to standardize the definition and classification of AKI, there is still inconsistency in the application of the criteria and the limitations of serum creatinine and urine output for detecting AKI is generally recognized by the medical community. In the future, biomarkers of renal cell injury may identify additional patients with AKI and may identify the majority of patients at an earlier stage.
NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is such a biomarker. It is a small protein expressed in neutrophils and certain epithelia, including the renal tubules. Renal expression of NGAL is dramatically increased in kidney injury from a variety of causes, and NGAL is released into both urine and plasma. NGAL levels rise within two hours of the insult, making NGAL an early and sensitive biomarker of kidney injury.
Due to the heterogeneous implementation of AKI definitions and classifications, a uniform definition will be applied to this investigation, to ensure comparative results between the enrollment sites.
The aim of the study is to validate the assigned NGAL cutoff value by comparing to clinical diagnosis of AKI as determined by current clinical practice in the US.
The study sites will enroll consecutive patients meeting the criteria below in an ICU or critical care setting. Patients are given standard clinical care and lab-work. Each day, one additional urine and two additional plasma samples will be drawn and frozen. These additional samples are shipped to Sponsor for retrospective NGAL measurements.
The duration of each subject´s participation will be until discharge from the ICU, or for a maximum 8 days, whichever comes first. In addition serum creatinine values will continue to be collected manually from the hospital data system for 48 hours after discharge from the ICU. (If subject has been in ICU for 8 or more days, the follow up values are collected while the patient is still in the ICU).
250 subjects will be enrolled in total at the three investigator sites. At least 40 patients must be enrolled at each site.
The NGAL value will be matched to the "clinical diagnosis" of acute kidney injury (AKI) as specified by KDIGO® guidelines. The clinical diagnosis will be assigned by a three-person adjudication panel based on the entries in the eCRF by the investigators. Adjudicators are blinded for investigation site, AKI-diagnosis by treating physician, and NGAL values.
A comparison of AKI diagnosis based on the cutoff value 250 ng/mL and clinical diagnosis as assigned by the majority of the adjudication panel will be conducted.
.
Primary endpoints:
- Sensitivity of the NGAL test will be estimated as the proportion of patients with an observed NGAL value above or equal to 250 ng/ml among patients classified as having AKI, and.
- Specificity of the NGAL test will be estimated as the proportion of patients with an observed NGAL value below 250 ng/ml among patients classified as not having AKI
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Springfield, Massachusetts, Estados Unidos, 01199/01107
- Baystate Medical Center / WNERTA
-
-
New York
-
Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Methodist Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Admission to intensive care unit
- Informed consent
- Age ≥ 18 years.
Exclusion criteria:
- History of nephrectomy, renal transplantation and/or renal replacement therapy initiated before admission
- Males and females aged 17 years or below
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
NGAL (ng/mL)
Periodo de tiempo: Daily during ICU stay up to 8 days
|
Highest measured value used
|
Daily during ICU stay up to 8 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Creatinine
Periodo de tiempo: Daily during ICU stay up to 8 days + 2 days after discharge
|
Change from baseline/reference value calculated to be used in application of diagnostic AKI criteria and rating
|
Daily during ICU stay up to 8 days + 2 days after discharge
|
Urine output
Periodo de tiempo: 6h, 12h and 24h daily during ICU stay up to 8 days
|
Urine output calculated (mL/kg/h) to be used in application of diagnostic AKI criteria and rating
|
6h, 12h and 24h daily during ICU stay up to 8 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Peter A McCullough, M.D., St. John Providence Health System
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- KLIN 12-005
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .